Date: 2011-04-12
Type of information:
Compound: EB66® cell line for the production of a human vaccine candidate
Company: Vivalis (France) undisclosed worldwide vaccine company
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Vivalis has signed a research agreement with an undisclosed worldwide vaccine company, granting the rights to evaluate the EB66® cell line for the production of a human vaccine candidate.
Financial terms:
Latest news:
